Syndax Pharmaceuticals Reports Third Quarter 2020 Financial Results and Provides Clinical and Business Update

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 7/1/2026

1. SPY
2. NKE
3. NVDA
4. MU
5. AVAV
6. DLR
7. TSLA
8. EOSE
9. ABVX
10. VSH

Go back to Syndax Pharmaceuticals Reports Third Quarter 2020 Financial Results and Provides Clinical and Business Update

Syndax Pharmaceuticals (SNDX) Misses Q3 EPS by 2c

November 2, 2020 4:53 PM EST

Syndax Pharmaceuticals (NASDAQ: SNDX) reported Q3 EPS of ($0.46), $0.02 worse than the analyst estimate of ($0.44).

"We continue to make exciting progress in the Phase 1 portion of the AUGMENT-101 trial of SNDX-5613, our highly selective, potent, oral menin inhibitor, in adult and pediatric patients with acute leukemias that harbor... More